Nuformix PLC NXP004 Update (2214K)

TIDMNFX

RNS Number : 2214K

Nuformix PLC

20 December 2022

Nuformix plc

("Nuformix" or the "Company")

NXP004 Update

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following update regarding the Company's NXP004 programme, focused on the development of novel, proprietary, cocrystal forms of olaparib, a drug currently marketed by AstraZeneca, under the Lynparza(R) brand name.

Lynparza(R) is approved for treatment of an increasing number of cancers, achieving sales of US$2.7bn in 2021 with industry analysts forecasting annual sales of US$9.7bn by 2028. However, olaparib's very low aqueous solubility has presented challenges historically in terms of "pill burden" and low olaprib bioavailability with Lynparza(R) already having been reformulated once whilst on market. In spite of reformulation, olaparib's bioavailability in the currently marketed Lynparza(R) formulation remains unknown, but data indicate low and variable drug exposure in humans.

The Company has filed two patent applications covering novel forms of olaparib with the potential of protection out to 2041 and has previously demonstrated the enhanced dissolution performance of all NXP004 cocrystals versus crystalline olaparib drug substance.

Having identified two lead cocrystals for progression, the Company recently announced commencement of work to scale-up production and directly compare in-vitro dissolution performance of its lead cocrystals to the marketed Lynparza(R) tablet product using a biologically relevant dissolution design and with drug loading relevant to human dosing.

The Company is pleased to announce that the results from these studies demonstrate that the two lead NXP004 cocrystals selected out-perform Lynparza (R), both in terms of rate and extent of dissolution and release of olaparib.

Enhancement of dissolution in the currently marketed formulation of Lynparza (R) resulted in improved bioavailability versus the initial marketed product. Therefore, the NXP004 programme may offer potential to further increase olaparib bioavailability. In addition, the potential simplicity of NXP004-based formulations may offer improvements in product cost-of-goods versus the currently marketed product, which requires complex manufacturing methods.

These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic products.

The Company will now consider the design and execution of suitable pre-clinical pharmacokinetic models to further investigate and validate NXP004's potential for enhancing the oral absorption of olaparib. Securing these data will enable commencement of discussions with multiple potential commercialisation partners.

Further updates will be announced in due course, as appropriate .

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: " I'm delighted with the results of the head-to-head dissolution studies, which exceeded my expectations and have demonstrated first-time that the lead NXP004 cocrystals offer significant scope for enhanced performance versus Lynparza (R) , for which biorelevant dissolution data is not in the public domain. The NXP004 cocrystals studied demonstrate some of the best dissolution performance I've seen from application of the technology - a step-change in dissolution performance, yet they appear to lack any of the common drawbacks that can hamper development of cocrystal-based products, which is surprising. These new data strongly support progression of the programme and we will now look to translate these enhancements into an in-vivo setting, which if successful will position the Company well for commencing partnering discussions with multiple potential partners identified."

Enquiries:

 
 Nuformix plc 
 Dr Dan Gooding, Executive Director         Via IFC Advisory 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  +44 (0) 20 3650 3650 
 John Howes (Corporate Broking)             +44 (0) 20 3650 3652 
 IFC Advisory Limited 
 Tim Metcalfe                               +44 (0) 20 3934 6630 
  Zach Cohen                                 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDQKLFFLLLXFBF

(END) Dow Jones Newswires

December 20, 2022 02:00 ET (07:00 GMT)

Nuformix (LSE:NFX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025